Introduction to Biomarkers

What are Biomarkers?

Key components for personalized medicine

Biomarkers are referred to as any substance, structure or process that can be analyzed in the body and helps in predicting disease. Biomarkers have a crucial role in the early detection, diagnosis, and management of treatment for major diseases like cancer and heart diseases.

Biomarkers can include:

  • Genetic mutations or alterations in DNA
  • Proteins or enzymes produced by cancer cells
  • Patterns of gene expression
  • Specific molecules found in blood, tissue, or other body fluids

Importance for LMS Patients

For leiomyosarcoma (LMS) patients, molecular tumor testing can provide critical insights that may influence treatment decisions and access to clinical trials. As a rare cancer, LMS treatment can benefit significantly from a personalized approach guided by molecular testing.

Benefits of Molecular Testing

Why testing matters for LMS patients

  • Identify potential targeted therapy options
  • Determine eligibility for clinical trials
  • Better understand tumor behavior and prognosis
  • Guide treatment decisions based on tumor characteristics
  • Monitor treatment response and detect recurrence

"Molecular testing revealed a specific mutation in my tumor that made me eligible for a targeted therapy clinical trial. This personalized approach has given me hope and more treatment options."

- LMS Patient, Denver Support Group

Types of Molecular Testing

Several types of molecular testing can be used to analyze tumor samples and identify important biomarkers in LMS:

Next-Generation Sequencing (NGS)

Comprehensive genetic analysis

Analyzes multiple genes simultaneously to identify mutations, amplifications, deletions, and other genetic alterations that may drive cancer growth. This technology can sequence entire genomes or targeted panels of genes relevant to LMS.

Advanced Technique

Immunohistochemistry (IHC)

Protein detection method

Uses antibodies to detect specific proteins in tissue samples, helping to identify biomarkers that may be targets for therapy or indicators of prognosis. This technique can visualize protein expression patterns in tumor cells.

Standard Technique

Gene Expression Profiling

Activity measurement

Measures the activity levels of multiple genes to create a molecular "signature" that can help predict tumor behavior and response to treatment. This approach analyzes which genes are actively being transcribed in tumor cells.

Advanced Technique

Liquid Biopsy

Non-invasive blood testing

Analyzes circulating tumor DNA (ctDNA) in blood samples to monitor treatment response, detect recurrence, or identify genetic alterations without invasive tissue sampling. This emerging approach offers a less invasive alternative to traditional biopsies.

Emerging Technique

Note: Special Video on Circulating DNA for Sarcomas by Panel of Experts

Link to Video

Note: The availability of these testing methods may vary by location. Discuss with your oncologist which tests are appropriate for your specific situation.

Research Partnerships

NLMSF has established partnerships with leading organizations to improve access to molecular testing and targeted therapies for LMS patients.

BostonGene

Personalized Cancer Care Through Genomic Profiling

BostonGene

Delivers comprehensive genomic profiling to match cancer patients with biomarker-driven therapies and clinical trials.

Visit Website
Key Features:
  • Tumor Portrait™ test analyzes DNA/RNA across 22,000 genes
  • Personalized treatment and clinical trial recommendations
  • Identifies prognostic and germline alterations
  • Financial assistance program for patients
  • ASCO/NCCN guideline-recommended testing
  • Secure report delivery to physicians
Resources:

Signatera

Early Cancer Recurrence Detection with Personalized ctDNA Testing

Signatera

A personalized ctDNA test that detects molecular residual disease (MRD) to identify cancer recurrence earlier than standard tools.

Visit Website
Key Features:
  • Custom-built MRD assay using tumor-specific mutations
  • Detects recurrence 4-10 months before imaging
  • Monitors treatment response, including immunotherapy
  • Medicare coverage for multiple solid tumors
  • 7-10 day turnaround for serial blood tests
  • Financial assistance for eligible patients
Resources:

Target Cancer Foundation

Collaborative Partnership

Supporting LMS research

NLMSF has established a proactive collaborative partnership with Target Cancer Foundation on behalf of the LMS Patient community. This foundation is dedicated to supporting rare cancer research and improving access to precision medicine for patients with rare and understudied cancers.

Visit Target Cancer Foundation Website

TRACK Trial

An open label, non-randomized, multi-center, pragmatic study that aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

Key Features:

  • Remote consent and participation approach
  • Available for all patients with rare tumors within the United States
  • Traditional, site-based patient consenting also available

Resources:

TRACK Trial Webinar2020 AnnouncementClinical Trials.gov

Perthera

Matching Patients to Optimal Therapies * Intelligence for Optimum Outcomes

Perthera

Provides precision oncology services that help match patients to optimal therapies based on molecular testing results.

Visit Website
Key Features:
  • Precision Oncology services at no cost to patients or oncologists
  • Clinical coordination, AI and data analytics
  • Molecular tumor board
  • Report delivery included in concierge services
  • Less than 3 days average turnaround time
  • HIPAA compliant patient data protection
Resources:

Frequently Asked Questions

What lab does the testing? How many mutations do they test for?

Perthera is not a Lab. We are Lab agnostic and will use the ordering Oncologist's preferred Lab or one of our own. The ordering physician determines how many panels/mutations they would like us to test. Lab testing is put through a patient's insurance, often with no balance billing.

How much does it cost?

Perthera delivers our Precision Oncology services at no cost to patients or oncologists.

Is the patient's data confidential or do they sell it?

We fully comply with all HIPAA requirements and maintain strict confidentiality with all patient data.

Next Steps

If you're considering molecular testing for your leiomyosarcoma, here are some recommended steps:

1

Discuss with Your Oncologist

Talk to your oncologist about the potential benefits of molecular testing for your specific situation.

2

Explore Testing Options

Research the different types of molecular testing available and which might be most appropriate for your case.

3

Check Insurance Coverage

Contact your insurance provider to understand coverage for molecular testing and any potential out-of-pocket costs.

4

Consider Clinical Trials

Explore clinical trials like the TRACK Trial that may provide access to molecular testing and targeted therapies.

5

Connect with Resources

Reach out to NLMSF, Target Cancer Foundation, or Perthera for additional support and guidance.

Additional Resources

Explore these additional resources to learn more about molecular testing and precision medicine for leiomyosarcoma:

Molecular Testing Guide

A comprehensive guide to understanding molecular testing for sarcoma patients.

Download PDF

Webinar: Precision Medicine for LMS

An educational webinar featuring experts discussing the latest advances in precision medicine for LMS.

Watch Webinar

Questions to Ask Your Doctor

A list of important questions to ask your healthcare team about molecular testing.

View Questions

LMS Biomarker Research

Latest research on biomarkers and molecular targets in leiomyosarcoma.

Read Research

Telemedicine Clinics

Virtual Sarcoma Clinic

Serving: Nationwide

Access expert sarcoma care from anywhere in the United States through virtual consultations with specialized oncologists.

Sarcoma Telehealth Institute

Serving: West Coast

Specialized in providing telehealth services for sarcoma patients with a focus on molecular testing and precision medicine.

Virtual Second Opinion Resources

Getting a second opinion at a sarcoma center is crucial. Many hospitals now offer virtual second opinions, making it easier to access expert opinions without the need for travel.

Sarcoma Second Opinion Service

Expert reviews of your medical records, no travel required.

Cancer eConsults

Virtual consultations with top oncologists nationwide.

Learn More